Innovative Surgical Platform Virtual Incision's development of MIRA, a miniature, highly accessible robotic-assisted surgery platform authorized by the FDA, presents a compelling opportunity to partner with healthcare providers seeking cutting-edge, minimally invasive surgical solutions to enhance patient outcomes.

Expanding Market Reach With recent expansion of its offices in Lincoln, Nebraska, and nearing the commercialization phase supported by over 87 million dollars in funding, the company is positioned for growth, making it an ideal partner to provide advanced surgical robotics to hospitals planning to upgrade their operating rooms.

Strategic Leadership The appointment of new CEO Jim Alecxih in June 2025 and key medical officer Piet Hinoul signifies a focus on strategic growth and clinical market penetration, offering sales teams a clear pathway for collaboration with key decision-makers in the company's leadership.

Recognition & Credibility Receiving the Governor’s Bioscience Award in 2024 boosts Virtual Incision’s credibility within the biotech and medical device sectors, presenting opportunities to align with government-backed innovation initiatives or funding opportunities for healthcare institutions.

Market Potential & Funding With a revenue estimate between 10 and 25 million dollars and a strong funding foundation, Virtual Incision is preparing for product launches that can revolutionize surgical procedures, creating demand among hospitals and surgical centers eager to adopt next-generation robotic systems.